Compare Gigacloud Technology Inc (GCT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs TG Therapeutics Inc — how do they compare? Gigacloud Technology Inc trades at $57.26 (market cap $2.02B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and TG Therapeutics Inc for 16 Days on average.
| GCT | TGTX | |
|---|---|---|
Market Cap | $2.02B | $8.16B |
Volume | 1,020,985 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $56.42 | $59.06 |
52-Week Low | $25.46 | $26.94 |
Typical Hold Time | 21 Days | 16 Days |
Enterprise Value | $2.14B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.26, up 2.32% today, with a bullish technical outlook and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock shows robust profitability with a 10.65% net income margin and 32.34% ROE, supported by positive cash flow from operations of $190.66 million in 2025. Recent news highlights institutional interest and expansion into European markets.
The outlook is positive with revenue growth to $1.5 billion projected for 2026 and a consensus analyst price target of $32.50, though risks include insider selling and competitive pressures in the consumer discretionary sector. The stock's current price near resistance at $58 suggests potential for volatility amid overbought short-term conditions.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
